CASTLE BIOSCIENCES INC CSTL

Healthcare SIC 8071 - Services-Medical Laboratories NAICS Health Care and Social Assistance › Ambulatory Health Care Services › Medical and Diagnostic Laboratories › Medical Laboratories derived Nasdaq

Castle Biosciences is a molecular diagnostics company offering innovative test solutions to aid clinicians in the diagnosis and treatment of dermatologic cancers, Barrett's esophagus ("BE"), atopic dermatitis ("AD"), uveal melanoma ("UM").

Since our inception in 2008, it has been our vision to transform disease management by keeping people first: patients, clinicians, employees and investors. This foundational strategy remains the guidepost for the direction of our company and the basis of long-term value creation.

Our tests are designed to deliver personalized information to help better inform clinical care decisions. For our core tissue-based tests, we use multi-analyte assays with algorithmic analysis ("MAAA") to characterize an individual patient's biology and generate clinically actionable information. Depending on the specific test, this information may be used to provide information to help guide treatment and patient management decisions including potential responsiveness to therapy and to assist in the diagnosis of a disease.

Last close 33.08 2026-10-23
Market cap $1.01B 2026-06-30 share count
52-week range 17.72 - 44.28

Valuation FY2025 figures against the last close

P/S2.9x
P/E—
P/FCF35.7x
EV/EBITDA—
Dividend yield—
Diluted EPS-0.83

Annual financial statements

Income statement

Fiscal year FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017
Revenue $344.2M$332.1M$219.8M$137.0M$94.1M$62.6M$51.9M$22.8M—
Cost of revenue $71.0M$60.2M$45.0M$32.0M$15.8M$9.7M$7.3M$5.3M—
Gross profit $273.2M$271.9M$174.8M$105.0M$78.3M$53.0M$44.6M$17.5M—
R&D $51.9M$52.0M$53.6M$44.9M$29.6M$13.3M$7.4M$4.9M—
SG&A $229.3M$200.0M$180.2M$143.0M$86.7M$48.1M$29.8M$16.5M—
Total operating expenses ——————$37.2M$21.3M—
Operating income -$42.8M$8.7M-$68.0M-$72.9M-$40.1M-$6.5M$7.3M-$3.8M—
Interest expense $86.0K$577.0K$11.0K$17.0K$1.0K$2.6M$4.6M$2.3M—
Pre-tax income -$18.8M$21.6M-$57.4M-$65.4M-$22.6M-$10.2M$5.3M-$6.4M—
Income tax $5.4M$3.3M$101.0K$1.8M$8.7M$84.0K$72.0K$9.0K—
Net income -$24.2M$18.2M-$57.5M-$67.1M-$31.3M-$10.3M$5.3M-$6.4M—
EPS, basic -0.830.66-2.14-2.58-1.24-0.540.35-5.33—
EPS, diluted -0.830.62-2.14-2.58-1.24-0.54-0.21-5.33—
Shares, diluted (wtd. avg.) 29.0M29.3M26.8M26.1M25.1M18.9M8.7M1.9M—

Balance sheet

Fiscal year FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017
Cash and equivalents $116.7M$119.7M$98.8M$122.9M$329.6M$409.9M$98.8M$4.5M$1.2M
Short-term investments $171.6M$169.9M$144.3M$135.7M$0————
Receivables $43.4M$51.2M$38.3M$23.5M$17.3M$12.8M$14.6M$12.1M—
Inventory $10.3M$8.1M$7.9M$4.0M$2.0M$2.2M$1.2M$882.0K—
Total current assets $361.1M$360.2M$295.6M$292.3M$353.7M$429.6M$116.7M$18.1M—
Property, plant and equipment ———$14.3M$9.5M$7.1M$2.1M$1.5M—
Goodwill $10.7M$10.7M$10.7M$10.7M$0————
Other intangibles $88.9M$95.5M$106.6M$115.7M$88.9M$0$0$4.0K—
Total assets $578.6M$531.2M$453.3M$447.3M$462.6M$439.3M$119.7M$22.4M—
Accounts payable $18.7M$6.9M$10.3M$4.7M$2.5M$2.1M$1.9M$1.5M—
Short-term debt $417.0K$278.0K$0——$0$5.8M$0—
Total current liabilities $68.7M$49.4M$47.7M$36.1M$24.9M$20.9M$15.3M$6.7M—
Long-term debt $9.6M$9.7M$0——$0$19.3M$24.5M—
Total liabilities $107.7M$75.4M$62.1M$48.2M$50.8M$23.6M$34.6M$32.5M—
Retained earnings -$224.3M-$200.1M-$218.4M-$160.9M-$93.8M-$62.5M-$52.2M-$57.5M—
Total equity $470.9M$455.8M$391.3M$399.1M$411.7M$415.7M$85.1M-$56.6M-$50.3M

Cash flow

Fiscal year FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017
Operating cash flow $64.3M$64.9M-$5.6M-$41.7M-$19.0M$9.9M$7.0M-$12.3M—
Depreciation and amortisation $40.8M$16.0M$12.3M$10.5M$3.4M$472.0K$354.0K$287.0K—
Stock-based compensation $45.9M$50.3M$51.2M$36.3M$21.7M$8.3M$1.2M$294.0K—
Capital expenditure $36.0M$28.3M$13.6M$5.6M$3.5M$4.8M$937.0K$277.0K—
Investing cash flow -$60.4M-$50.1M-$16.2M-$166.5M-$66.7M-$4.7M-$937.0K-$277.0K—
Financing cash flow -$7.0M$6.1M-$2.3M$1.5M$5.4M$305.9M$88.3M$15.8M—

Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001628280-26-024166.

Plot the figures US dollars

Income statement Revenue Cost of revenue Gross profit R&D SG&A Total operating expenses Operating income Interest expense Pre-tax income Income tax Net income EPS, basic EPS, diluted Shares, diluted (wtd. avg.)
Balance sheet Cash and equivalents Short-term investments Receivables Inventory Total current assets Property, plant and equipment Goodwill Other intangibles Total assets Accounts payable Short-term debt Total current liabilities Long-term debt Total liabilities Retained earnings Total equity
Cash flow Operating cash flow Depreciation and amortisation Stock-based compensation Capital expenditure Investing cash flow Financing cash flow Dividends paid Buybacks
  • Revenue
  • Gross profit
  • Net income
Revenue, Gross profit, Net income by fiscal year, in US dollars The same figures are in the table below this chart. -200M 0 200M 400M Revenue, FY2018: 22.8M Gross profit, FY2018: 17.5M Net income, FY2018: -6.4M Revenue, FY2019: 51.9M Gross profit, FY2019: 44.6M Net income, FY2019: 5.3M Revenue, FY2020: 62.6M Gross profit, FY2020: 53M Net income, FY2020: -10.3M Revenue, FY2021: 94.1M Gross profit, FY2021: 78.3M Net income, FY2021: -31.3M Revenue, FY2022: 137M Gross profit, FY2022: 105M Net income, FY2022: -67.1M Revenue, FY2023: 219.8M Gross profit, FY2023: 174.8M Net income, FY2023: -57.5M Revenue, FY2024: 332.1M Gross profit, FY2024: 271.9M Net income, FY2024: 18.2M Revenue, FY2025: 344.2M Gross profit, FY2025: 273.2M Net income, FY2025: -24.2M FY2017 FY2018 FY2019 FY2020 FY2021 FY2022 FY2023 FY2024 FY2025
Fiscal year FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Revenue — $22.8M $51.9M $62.6M $94.1M $137.0M $219.8M $332.1M $344.2M
Gross profit — $17.5M $44.6M $53.0M $78.3M $105.0M $174.8M $271.9M $273.2M
Net income — -$6.4M $5.3M -$10.3M -$31.3M -$67.1M -$57.5M $18.2M -$24.2M

Recent filings and events

  • Results announced The quarterly or annual earnings release. Arrives four times a year from almost every company here. Item 2.02
  • Regulation FD disclosure Something the company told the market and had to tell everyone at once - usually a slide deck or a press release. Item 7.01
  • Shareholder vote The results of the annual meeting or a special vote. Item 5.07
  • Results announced Item 2.02
  • Regulation FD disclosure Item 7.01
  • Annual report filed A new 10-K. The figures and the business description on this site come from it. Form 10-K
  • Results announced Item 2.02
  • Regulation FD disclosure Item 7.01
  • Results announced Item 2.02
  • Regulation FD disclosure Item 7.01
  • Results announced Item 2.02
  • Regulation FD disclosure Item 7.01

Item numbers are Form 8-K's own, and a filing date is up to four business days after the thing it reports. The same feed across the whole market.

Others in SIC 8071

TickerCompanyMarket capP/ERevenue growth
NTRA Natera, Inc. $58.23B — 35.9%
DGX QUEST DIAGNOSTICS INC $26.70B 27.6x 11.8%
LH LABCORP HOLDINGS INC. $26.68B 31.4x 7.2%
GH Guardant Health, Inc. $22.69B — 32.9%
CAI Caris Life Sciences, Inc. $9.04B — 97.0%
GRAL GRAIL, Inc. $5.92B — 17.2%
RDNT RadNet, Inc. $5.54B — 11.5%
BLLN BillionToOne, Inc. $5.00B 769.8x 100.0%